Christopher Bunce

Prof

  • Professor of Translational Cancer Biology and Director of Research, Biosciences

Accepting PhD Students

PhD projects

Chris Bunce directs a translational research group dedicated to the development of novel therapies for leukaemias and lymphomas. A particular focus is the exploitation of drug redeployment strategies using off-patent drugs to provide affordable therapies that can be exploited by all, including the world's poorer nations.

A particular focus in Professor Bunce’s translational leukaemia and lymphoma research is the use of old drugs for new diseases. Drug redeployment endeavours to use relatively cheap available drugs and to use them in new ways. His group's approach is to take drugs that are not considered as anti-cancer drugs and to use them in combinations that generate an anti-cancer effect. The group's most advanced project is the use of the contraceptive drug medroxyprogesterone acetate combined with a cholesterol lowering drug Bezafibrate. This remarkable drug combination is now in clinical trials for the treatment of acute myeloid leukemia here in the UK and for Burkitt lymphoma in Malawi.

1982 …2024

Research activity per year

Network

Geoff Brown

Person: Honorary

Scott White

Person: Academic

Laura O'Neill

Person: Academic

Andrew Southam

Person: Academic

Michael Finney

Person: Academic

Nicholas Barnes

  • Pharmacy - Professor of Neuropharmacology

Person: Academic

Martin Hewison

Person: Academic

Paul Moss

Person: Academic

Helen Parry

Person: Academic

Nikolas Hodges

Person: Academic

Andrew Lovering

Person: Academic

Robert Hills

Person: Honorary

P. J. French

  • AstraZeneca

External person

L. A. Conroy

  • University of Birmingham

External person

G. J. Morgan

  • University of Arkansas for Medical Sciences
  • NYU Langone Medical Center
  • New York University

External person

J. A. Creba

  • University of Birmingham
  • INSERM

External person

Walter M Gregory

  • University of Leeds

External person

Anthony J Child

  • University of Leeds

External person

Guy E D Pratt

  • University Hospital Birmingham NHS Foundation Trust

External person

Graham H Jackson

  • Newcastle University

External person

Roger G. Owen

  • Leeds Teaching Hospitals NHS Trust

External person

G. R. Guy

  • University of Birmingham
  • Department of Biochemistry

External person

Martin F. Kaiser

  • Royal Marsden Hospital
  • Institute for Cancer Research
  • Royal Marsden NHS Foundation Trust

External person

John Ankers

  • University of Liverpool

External person

P. Allen

  • King’s College London

External person

Robert A Stockley

  • Queen Elizabeth Hospital Birmingham
  • General Hospital
  • University Hospital Birmingham NHS Foundation Trust

External person

David A Cairns

  • University of Leeds

External person

P. O. Berggren

  • Karolinska Institutet

External person

Jonathan J. Sheard

  • Aston University

External person

Abe Jacob

  • Royal Wolverhampton Hospitals NHS Trust

External person

T. Nilsson

  • Fundamental Fysik
  • Chalmers University of Technology

External person

Francesco Falciani

  • Centre for Computational Biology and Modelling
  • Institute for Integrative Biology
  • University of Liverpool

External person

Max A. Ellington

  • University of Chester

External person

MK Tse

  • Massachusetts Institute of Technology

External person

Deniz Toksoz

  • University of Birmingham

External person

Zaheer Afzal

  • University of Birmingham

External person

Martyn A. Snow

  • The Royal Orthopaedic Hospital NHS Foundation Trust

External person

Martin Hrabé de Angelis

  • Technical University Munich

External person

William E. Johnson

  • University of Chester
  • Chester Medical School

External person

M Cook

  • DEM Solutions Ltd

External person

Claire E Stewart

  • Liverpool John Moores University

External person